Sanofi’s Genzyme recently announced that treatment with its Cerdelga (eliglustat) reduced spleen size 28 percent compared to placebo in patients with Gaucher disease. The company announced that results from the ENGAGE registration study evaluating Cerdelga in treatment-naïve patients with Gaucher disease type 1 were published in The Journal of the …